Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades

Purpose: The impact of changes in therapy for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on the prevalence of physical performance limitations and participation restrictions among survivors is unknown. We aimed to describe the prevalence of reduced function among ALL and NHL survivors by treatment era. Methods: Participants included survivors of childhood ALL and NHL, and a cohort of their siblings, participating in the Childhood Cancer Survivor Study (CCSS). Physical function was measured using questionnaire. The prevalence of reduced function was compared to siblings using generalized estimating equations, overall and stratified by treatment decade. Associations between organ system–specific chronic conditions (CTCAE v4.03) and function were also evaluated. Results: Among 6511 survivors (mean age 25.9 years (standard deviation 6.5)) and 4127 siblings, risk of performance limitations (15.2% vs. 12.5%, prevalence ratio [PR] = 1.5, 95%CI = 1.3–1.6), restrictions in personal care (2.0% vs. 0.6%, PR = 3.1, 95% CI = 2.0–4.8), routine activities (5.5% vs. 1.6%, PR = 3.6, 95% CI = 2.7–4.8), and work/school attendance (8.8% vs. 2.1%, PR = 4.5, 95% CI = 3.6–5.7) was increased in survivors vs. siblings. The prevalence of survivors reporting reduced function did not decrease between the 1970s and 1990s. The presence of neurological and cardiovascular conditions was associated with reduced function regardless of treatment decade. Conclusions: Despite changes in therapy, the prevalence of poor physical function remained constant between the 1970s and 1990s. The CCSS clinical trial registration number is NCT01120353 (registered May 6, 2010). Implications for Cancer Survivors: Our findings support screening for reduced physical function so that early interventions to improve physical performance and mitigate chronic disease can be initiated.